Juvenile Idiopathic Arthritis (JIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis, refers to a group of conditions involving joint inflammation (arthritis) that first appear before age 16. The term "idiopathic" indicates that the specific cause of the disorder is unknown. Researchers have identified changes in several genes that may influence the risk of developing juvenile idiopathic arthritis. Some of these genes belong to a family of genes that provide instructions for making a group of related proteins called the human leukocyte antigen (HLA) complex.
·
The incidence of Juvenile idiopathic arthritis
(JIA) in North America and Europe is estimated to be 4 to 16 in 10,000 children
Thelansis’s
“Juvenile Idiopathic Arthritis (JIA) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Juvenile
Idiopathic Arthritis (JIA) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Juvenile Idiopathic
Arthritis (JIA) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Juvenile
Idiopathic Arthritis (JIA) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Juvenile
Idiopathic Arthritis (JIA), Juvenile Idiopathic Arthritis (JIA) market outlook, Juvenile Idiopathic Arthritis (JIA) competitive landscape, Juvenile Idiopathic Arthritis
(JIA) market forecast, Thelansis, Primary market
research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment